The role in understanding the role that THC in pharmaceutical-grade cannabis plays in treating pain takes another step forward. The Regina Leader Post published an article about a recent study conducted in The Netherlands regarding pain mitigation for fibromyalgia patients.
A study out of the Netherlands found that standardised pharmaceutical-grade cannabis with a high tetrahydrocannabinol (THC) content was effective in treating the musculoskeletal pain caused by fibromyalgia.
Conducted by Leiden University Medical Centre (LUMC) in co-operation with Bedrocan International, the study involving the pharmaceutical-grade cannabis provided by the company further found “cannabis flos with only cannabidiol (CBD) did not provide the patients with relief.”
The research involved a total of 20 patients treated at four distinct moments, as well as the administration of three different cannabis products provided by Bedrocan and placebo (cannabis without the main active substances THC and CBD) by a vaporizer.